糖代谢与睾酮关系的研究进展

doi:10.3969/j.issn.1003-9198.2022.08.023

摘要/Abstract

中图分类号:

包宇航, 郑仁东. 糖代谢与睾酮关系的研究进展[J]. 实用老年医学, 2022, 36(8): 850-853.

[1] LI Y, ZHANG M, LIU X, et al. Correlates and prevalence of hypogonadism in patients with early- and late-onset type 2 diabetes[J]. Andrology, 2017, 5(4):739-743.
[2] BASARIA S. Male hypogonadism [J]. Lancet, 2014, 383(9924):1250-1263.
[3] 曹琳, 郑仁东, 刘克冕, 等. 男性2型糖尿病患者合并低促性腺激素性性腺功能减退的临床观察[J].中国糖尿病杂志, 2017, 25(5): 436-439.
[4] 朱春景, 陈云霞, 刘春燕, 等. 探讨男性睾酮水平在不同患者中的差异[J].甘肃医药,2019,38(6):495-497.
[5] FERNÁNDEZ-MIR M, CHILLARÓN J J, PEDRO-BOTET J. Testosterone deficiency, metabolic syndrome and diabetes mellitus[J]. Med Clin: Barc, 2016, 146(2):69-73.
[6] LIU X, JIANG J, LIU X, et al. Association of serum testosterone with different classes of glucose metabolism and the mediation effect of obesity: the henan rural cohort study[J]. Diabetes Metab Res Rev, 2019, 35(5):e3133.
[7] RASMUSSEN J J, SELMER C, FRSSING S, et al. Endogenous testosterone levels are associated with risk of type 2 diabetes in women without established comorbidity[J]. J Endocr Soc, 2020, 4(6):bvaa050.
[8] ZHENG R, CAO L, CAO W, et al. Risk factors for hypogonadism in male patients with type 2 diabetes[J]. J Diabetes Res, 2016. DOI:10.1155/2016/5162167.
[9] HAIDER K S, HAIDER A, SAAD F, et al. Remission of type 2 diabetes following long-term treatment with injectable testosterone undecanoate in patients with hypogonadism and type 2 diabetes: 11-year data from a real-world registry study[J]. Diabetes Obes Metab, 2020, 22(11):2055-2068.
[10] RAMACHANDRAN S, HACKETT G I, STRANGE R C. Testosterone replacement therapy: pre-treatment sex hormone-binding globulin levels and age may identify clinical subgroups[J]. Andrology, 2020, 8(5):1222-1232.
[11] GIAGULLI V A, CASTELLANA M, CARBONE M D, et al. Weight loss more than glycemic control may improve testosterone in obese type 2 diabetes mellitus men with hypogonadism[J]. Andrology, 2020, 8(3):654-662.
[12] 朱宇旌, 丁兰, 张勇, 等. 胰岛素对促性腺激素释放激素分泌及活性的调控[J].动物营养学报,2013, 25(1):1-7.
[13] BHATIA V, CHAUDHURIA, TOMAR R,et al. Low testosterone and high C-reactive protein concentrations predict low hematocrit in type 2 diabetes[J]. Diabetes Care, 2006, 29(10):2289-2294.
[14] FERNANDES G S, GERARDIN D C, ASSUMPO T A, et al. Can vitamins C and E restore the androgen level and hypersensitivity of the vas deferens in hyperglycemic rats?[J]. Pharmacol Rep, 2011, 63(4):983-991.
[15] FERNANDES G S, FERNANDEZ C D, CAMPOS K E, et al. Vitamin C partially attenuates male reproductive deficits in hyperglycemic rats[J]. Reprod Biol Endocrinol, 2011, 9:100.
[16] MOHAMMADI A, BEHNAM-RASSOULI M, MOMENI Z, et al. Effects of hydro-alcoholic extract of Launaea acanthodes on serum gonadotropin and testosterone levels and the structure of seminiferous tubules in hyperglycemic rats[J]. Chin J Integr Med, 2016, 22(3):207-213.
[17] KELLY D M, JONES T H. Testosterone and obesity[J]. Obes Rev, 2015, 16(7):581-606.
[18] GOEL P, POPA A R. The relation between metabolic syndrome and testosterone level[J]. Rom J Diabetes Nutr Metab Dis, 2018, 25(1):109-114.
[19] STÁRKA L, HILL M, POSPÍŠILOV H, et al. Estradiol, obesity and hypogonadism[J]. Physiol Res, 2020, 69(Suppl 2):S273-S278.
[20] MOON H, CHOI I, KIM S, et al. Cross-sectional association between testosterone, sex hormone-binding globulin and metabolic syndrome: The Healthy Twin Study[J]. Clin Endocrinol: Oxf, 2017, 87(5):523-531.
[21] KELLY D M, JONES T H. Testosterone: a metabolic hormone in health and disease[J]. J Endocrinol, 2013, 217(3):R25-R45.
[22] MARCHI S, BITTREMIEUX M, MISSIROLI S, et al. Endoplasmic reticulum-mitochondria communication through Ca2+ signaling: the importance of mitochondria-associated membranes (MAMs)[J]. Adv Exp Med Biol, 2017, 997:49-67.
[23] TRAISH A M, ABDALLAH B, YU G. Androgen deficiency and mitochondrial dysfunction: implications for fatigue, muscle dysfunction, insulin resistance, diabetes, and cardiovascular disease[J]. Horm Mol Biol Clin Investig, 2011, 8(1):431-444.
[24] HARADA N, YODA Y, YOTSUMOTO Y, et al. Androgen signaling expands B-cell mass in male rats and B-cell androgen receptor is degraded under high-glucose conditions[J]. Am J Physiol Endocrinol Metab, 2018, 314(3):E274-E286.
[25] LIU S, SUN Q. Sex differences, endogenous sex-hormone hormones, sex-hormone binding globulin, and exogenous disruptors in diabetes and related metabolic outcomes[J]. J Diabetes, 2018, 10(6):428-441.
[26] FANELLI G, GEVI F, BELARDO A,et al. Metabolic patterns in insulin-sensitive male hypogonadism[J]. Cell Death Dis, 2018, 9(6):653.
[27] KURNIAWAN L B, ADNAN E, MULYONO W. Insulin resistance and testosterone level in Indonesian young adult males[J]. Rom J Intern Med, 2020, 58(2):93-98.
[28] 陈正方,宋歌, 刘蕾, 等. 男性高血压患者血清睾酮水平与胰岛素抵抗的相关性[J].实用医学杂志, 2018, 34(11):1868-1871.
[29] SOUTEIRO P, BELO S, OLIVEIRA S C, et al. Insulin resistance and sex hormone-binding globulin are independently correlated with low free testosterone levels in obese males[J]. Andrologia, 2018, 50(7):e13035.
[30] ŠIMONIENĖ D, PLATŪKIENE A, PRAKAPIENĖ E,et al. Insulin resistance in type 1 diabetes mellitus and its association with patient's micro- and macrovascular complications, sex hormones, and other clinical data[J]. Diabetes Ther, 2020, 11(1):161-174.
[31] 王国君, 杨占君, 杜群, 等. 改善胰岛素抵抗对中年男性2型糖尿病患者血清睾酮水平的影响[J].中国全科医学, 2012, 15(27):3118-3120.
[32] FINK J, MATSUMOTO M, TAMURA Y. Potential application of testosterone replacement therapy as treatment for obesity and type 2 diabetes in men[J]. Steroids, 2018, 138:161-166.
[34] LIUX, WEI D, JIANG J, et al. Associations of SRD5A1 gene variants and testosterone with dysglycemia: Henan Rural Cohort study[J]. Nutr Metab Cardiovasc Dis, 2020, 30(4):599-607.
[34] ELSAIED M A, MASALLAT D, ABDEL-HAMID I A. Correlation of adiponectin with testosterone in patients with and without type 2 diabetes and erectile dysfunction[J]. Am J Mens Health, 2019, 13(1):1557988318807049.
[35] SORIGUER F, RUBIO-MARTÍN E, FERNÁNDEZ D, et al. Testosterone, SHBG and risk of type 2 diabetes in the second evaluation of the Pizarra cohort study[J]. Eur J Clin Invest, 2012, 42(1):79-85.

糖代谢与睾酮关系的研究进展

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

Metrics

推荐阅读 10

[1]	张星星, 张海洋, 何小菁, 鲁翔. 不同肥胖指标与老年人糖尿病患病风险的调查研究[J]. 实用老年医学, 2024, 38(9): 940-943.
[2]	赵玉玲, 黄婧, 叶文春. 血清γ-氨基丁酸、胰岛素样生长因子-1对老年糖尿病前期病人心血管事件风险的交互作用分析[J]. 实用老年医学, 2024, 38(8): 816-820.
[3]	梁杉杉, 梁欢, 杨珊, 刘建凤. 老年T2DM病人肌少症发生与颈动脉粥样硬化的相关性研究[J]. 实用老年医学, 2024, 38(8): 826-830.
[4]	时雯, 朱平, 周洁, 颜婷, 黄玉杰, 严妍. 胰激肽原酶治疗老年2型糖尿病轻度认知功能障碍的疗效观察[J]. 实用老年医学, 2024, 38(6): 587-591.
[5]	郭淳, 易梦廷, 宗前兴, 周怡, 巫海娣, 莫永珍. 老年2型糖尿病病人6个月内低血糖风险预测模型的构建:一项纵向研究[J]. 实用老年医学, 2024, 38(6): 592-597.
[6]	包海童, 谈萍, 俞沛文, 刘娟, 丁国宪, 佟蔷薇, 王晓东. 基于老年综合评估的2型糖尿病病人衰弱影响因素分析[J]. 实用老年医学, 2022, 36(12): 1264-1268.
[7]	陈明珠, 许勤, 蔡英华. 老年糖尿病合并衰弱病人自我感受负担的现状及影响因素分析[J]. 实用老年医学, 2022, 36(12): 1269-1272.
[8]	祖丽胡玛尔·阿布都艾尼, 刘超. 老年糖尿病的流行病学特点[J]. 实用老年医学, 2022, 36(10): 973-977.
[9]	唐伟, 张子成. 老年糖尿病血糖监测技术新进展[J]. 实用老年医学, 2022, 36(10): 978-982.
[10]	徐千越, 胡云. 注射类降糖药物在老年糖尿病病人中的使用新进展[J]. 实用老年医学, 2022, 36(10): 983-985.
[11]	叶德梅, 张俊, 殷汉, 李玲. 老年糖尿病口服降糖药物新进展[J]. 实用老年医学, 2022, 36(10): 986-990.
[12]	李盖, 王雷, 孙新娟, 王天元, 陈金安. 老年2型糖尿病并发症的治疗新进展[J]. 实用老年医学, 2022, 36(10): 991-995.
[13]	俞匀, 唐伟, 娄青林. 不同发病年龄新诊断2型糖尿病病人临床特点分析[J]. 实用老年医学, 2022, 36(10): 1015-1018.
[14]	姚铸玲, 王志勇, 熊亚晴, 徐斐. 南京市老年人群高血压合并糖尿病的流行特征[J]. 实用老年医学, 2022, 36(8): 796-800.
[15]	仰孝群, 欧阳晓俊. 糖尿病与衰弱相关研究进展[J]. 实用老年医学, 2022, 36(7): 655-659.